There may be some light at the end of a long regulatory tunnel for Sanofi's ($SNY) Lemtrada. The company resubmitted its once-rejected multiple sclerosis treatment for FDA approval, hoping that a new analysis of old data will win over regulators. On Friday, the agency accepted Sanofi's supplemental application for consideration, and a 6-month review period follows. A final decision is expected in the fourth quarter of this year, the company said in a statement. Release (PDF) | More